Kezar Life Sciences, Inc.

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Clinical Advisory Committee
  • Pipeline
    • Overview
    • KZR-616
    • KZR-261
  • Our Science
    • Overview
    • Medical & Scientific Presentations
    • Publications
  • Clinical Trials
  • Investors & News
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Medical & Scientific Presentations

Our Science

Our Science

  • Overview
  • Medical & Scientific Presentations
  • Publications
Apr 11, 2022

Sec61 inhibitor KZR-834, an anti-cancer agent, exhibits immunomodulatory activity and combines with PD-1 blockade to further enhance immune responses

Kezar Life Sciences, Inc

American Association for Cancer Research Annual Meeting 2022

Nov 8, 2021

Clinical and Humanistic Burden of Dermatomyositis and Polymyositis in the US: A Systematic Literature Review

American College of Rheumatology Convergence

Virtual Meeting, 2021

Nov 8, 2021

Healthcare Resource Utilization and Costs of Dermatomyositis and Polymyositis in the US: A Systematic Literature Review

American College of Rheumatology Convergence

Virtual Meeting, 2021

Jun 2, 2021

KZR-616, A Selective Immunoproteasome Inhibitor for the Treatment of Systemic Lupus Erythematosus: Results From the Completed Dose Escalation Phase 1b Portion of the MISSION Study

Kezar Life Sciences, Inc.

European Congress of Rheumatology (EULAR) 2021

Apr 10, 2021

Quantitative Proteomic Profiling of Novel Anti-cancer Small Molecule Inhibitors of Sec61: Mechanistic Investigation and Biomarker Discovery

Kezar Life Sciences, Inc

American Association for Cancer Research Annual Meeting 2021

Apr 10, 2021

Prioritizing tumor types for clinical study of novel Sec61 inhibitors by searching for expression profiles of sensitive cell lines in tumor sample databases

Kezar Life Sciences, Inc

American Association for Cancer Research Annual Meeting 2021

Nov 9, 2020

Small Molecule Inhibitors of Sec61 Cotranslational Translocation Regulate Phagocytosis Checkpoint Molecule CD47

Kezar Life Sciences, Inc

SITC 35th Anniversary Meeting

Nov 5, 2020

Treatment of SLE With or Without Nephritis With the Immunoproteasome Inhibitor KZR-616: Updated Results of the MISSION Study

Kezar Life Sciences, Inc

American College of Rheumatology (ACR) Convergence 2020

Nov 5, 2020

KZR-616, a First-in-class Selective Inhibitor of the Immunoproteasome, Ameliorates Polymyositis in a Murine Model

Kezar Life Sciences, Inc

American College of Rheumatology (ACR) Convergence 2020

Nov 3, 2020

Blockade of Cytokine Production and Attenuation of Experimental Arthritis Progression by Novel Small Molecule Inhibitors of Sec61-Dependent Protein Secretion

Kezar Life Sciences, Inc

8th Annual Meeting of the International Cytokine & Interferon Society (Cytokines 2020)

RSS
  • 1
  • 2
  • 3
  • 4
  • Next »
Kezar Life Sciences, Inc.
  • About Us
  • Pipeline
  • Our Science
  • Clinical Trials
  • Investors & News
  • Careers
Contact Us

4000 Shoreline Court , Suite 300
South San Francisco, CA 94080

Linkedin Facebook Twitter YouTube

© 2022 Kezar Life Sciences, Inc. All Rights Reserved.

Privacy Policy Disclaimer Sitemap